Anakinra to Prevent CAR-T Neurotoxicity and CRS

Phase 2, open-label trial of anakinra in cytokine release syndrome (CRS), neurotoxicity and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Rate of Severe Neurotoxicities at 4 weeks and Proportion of patients able to avoid death or mechanical ventilation at 28 days. Started Oct 2019; status: active, not recruiting.